France's 2026 social security budget may restrict reimbursement for certain chronic illnesses, potentially impacting patients with long-term conditions not currently considered "non-exempt".
A new analysis shows semaglutide (Ozempic/Wegovy) slows kidney disease progression in type 2 diabetes patients, improving kidney function and survival rates, even with a history of cardiovascular events. The drug mimics GLP-1 hormones and is also popular for weight loss.
Journalist Kara Swisher explores medical advancements and lifestyle changes that promote healthy longevity, focusing on combating chronic diseases like heart disease, diabetes, and cancer, rather than pursuing immortality.
